Balyasny Asset Management’s Tourmaline Bio TRML Stock Holding History

Balyasny Asset Management’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-32,567	Closed	-$1.56M	–	3564
2025 Q3	$1.56M	Sell	32,567 -571,994	-95%	-$15.9M	﹤0.01%	1923
2025 Q2	$9.67M	Buy	604,561 +11,586	+2%	+$188K	0.01%	980
2025 Q1	$9.02M	Buy	+592,975	New	+$9.51M	0.01%	970
2024 Q2	–	Sell	-20,100	Closed	-$460K	–	3117
2024 Q1	$460K	Sell	20,100 -324,027	-94%	-$11.4M	﹤0.01%	2085
2023 Q4	$9.01M	Buy	344,127 +197,567	+135%	+$3.95M	0.02%	908
2023 Q3	$4.12M	Buy	146,560 +56,083	+62%	+$1.64M	0.01%	1167
2023 Q2	$2.75M	Buy	+90,477	New	+$2.31M	0.01%	1270

Balyasny Asset Management's TRML Position: Q4 2025 in Review

Balyasny Asset Management sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 32,567 shares — an estimated $1.56M sold.

Balyasny Asset Management first reported a position in TRML in Q2 2023 and held it in 7 quarters. The position peaked at $9.67M in Q2 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

Balyasny Asset Management reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
Balyasny Asset Management sold 32,567 Tourmaline Bio shares in Q4 2025, an estimated $1.56M.
Balyasny Asset Management first reported a position in Tourmaline Bio in Q2 2023 and held it in 7 quarters.
Balyasny Asset Management's Tourmaline Bio position peaked at $9.67M in Q2 2025.
0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.